ALXO ALX Oncology Net earnings per share growth this year

ALXO (ALX Oncology Holdings) - company brandmark

The annual EPS percentage change demonstrates revenue dynamics, where 68.00 reflects the latest value of the metric. Stable growth is supported by competent management effectively allocating capital toward R&D. The advantage of ALX Oncology Holdings (ALXO) lies in the creation of evorpacept, a safe drug that blocks tumor defenses. Development is being conducted in collaboration with global pharma behemoths, which strengthens the potential for combination cancer therapy.

ALX Oncology Holdings (ALXO): Net earnings per share growth this year from 07/04/2022 to 11/18/2026

Analytical breakdowns and data insights for company alxoncology.com (ALXO)

- current quotes and average value forecast:
Summary company analysis:ALXO (ALX Oncology)
Brand item of ALX Oncology Holdings

For ALX Oncology Holdings (ALXO), which is developing an innovative CD47-based immunotherapy system, this indicator determines the rate of change in net earnings per share. The metric measures annual EPS growth, separating sustainable financial development from short-term market noise. By analyzing the EPS growth dynamics compared to last year, an investor assesses the fundamental reliability of the business. A positive trend would confirm the commercial effectiveness of evopseritib's implementation, signaling the company's transition to becoming a new standard in oncology.

Key competitors

IBRX - Expected net earnings per share growth this year|Earnings per share growth in current year immunocore.com|Net earnings per share growth this year januxrx.com (JANX)|Earnings per share growth in current year Arcus Biosciences Inc (RCUS)|Net earnings per share growth this year Zymeworks Corp ZYME|Tango Therapeutics Inc - Net earnings per share growth this year|Earnings growth in current year Iovance Corp IOVA|IMTX - Earnings per share growth in current year|XNCR (xencor.com) - Earnings per share growth this year|Compass Therapeutics Corp (CMPX) - Earnings per share growth in current year|Earnings per share growth rate in current year Replimune Corp (REPL)|Net earnings per share growth this year LYEL|IPHA - Net earnings per share change in current year|Net earnings per share growth this year PYXS (Pyxis Oncology, Inc.)|Net earnings per one share growth for the current year CGEN|Earnings growth in current year IOBT (IO Biotech)|Earnings per share increase in current year STRO|minktherapeutics.com - Earnings growth in current year|Earnings per share growth rate in current year Werewolf Therapeutics, Inc.|Immix (IMMX) - Earnings per share growth in current year|cuebiopharma.com (CUE) - Earnings growth in current year|PDSB (PDS Biotechnology Corp) - Earnings growth in current year|Earnings growth in current year sonnetbio.com|Earnings per share growth in current year MAIA Biotechnology, Inc. (MAIA)|LIMN: Earnings per share trend in current year|LAVA Therapeutics - Net earnings per share growth this year|nextcure.com (NXTC) - Earnings per share growth rate in current year|LPTX - Earnings per share growth in current year|Expected net earnings per share growth this year Intensity Therapeutics, Inc. INTS|SNSE: Earnings growth in current year|Synthetic Biologics - Earnings per share increase in current year|GRTS (Gritstone bio) - Earnings growth in current year|KA (Kineta, Inc.) - Net earnings per one share growth for the current year|Earnings growth in current year NEXI|Turnstone Biologics Corp - Earnings per share growth this year|Earnings growth in current year VCNX (Vaccinex Inc)|Harpoon Therapeutics Corp (HARP) - Earnings per share growth rate in current year